Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy

Background:

• Poly(ADP-ribose)polymerase (PARP) inhibitors represent a new class of anticancer drugs.
• PARP enzymes are crucial in signaling DNA single-strand breaks, a key component of the DNA damage response pathway.
• Current clinical applications involve combination therapy with chemotherapy or as single agents exploiting synthetic lethality.

Purpose of the Study:

• To review existing data on PARP inhibitors.
• To explore the potential of PARP inhibitors as radio-sensitizing agents in cancer treatment.

Main Methods:

• Review of preclinical and clinical data on PARP inhibitors.
• Analysis of efficacy and toxicity in combination with chemotherapy.
• Evaluation of synthetic lethality approaches.
• Assessment of radio-potentiation potential.

Main Results:

• Clinical efficacy of PARP inhibitors in combination with chemotherapy is often limited by normal tissue toxicity.
• Single-agent activity has been observed in specific contexts, such as synthetic lethality.
• The role of PARP inhibitors in enhancing the effects of radiation therapy is an area of ongoing investigation.

Conclusions:

• PARP inhibitors have a significant role in DNA damage response pathways.
• Future development may focus on utilizing PARP inhibitors to potentiate radiotherapy.
• Optimizing the use of PARP inhibitors requires careful consideration of toxicity and therapeutic strategy.